Cipher Pharmaceuticals Inc.
CPH.TOTSXHealthcare● Active
$16.84
+$0.09(+0.54%)
Market Cap$427589862
P/E Ratio—
52W High$20.56
52W Low$11.98
Cipher Pharmaceuticals Inc. (CPH.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CPH.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.33
Est. $0.19 · +77.7%
Revenue
$0.02B
Est. $0.02B · +2.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
CPH.TO reports quarterly as a TSX-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.49B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.49B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.29 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $0.19 | $0.33 | +77.7% | $0.02B | $0.02B | +2.6% |
| ▲ Q1 FY2026 | Mar 12, 2026 | $0.21 | $0.70 | +228.8% | $0.02B | $0.02B | -1.4% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $0.21 | $0.30 | +43.8% | $0.02B | $0.02B | +4.5% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $0.21 | $0.30 | +41.1% | $0.02B | $0.02B | +1.2% |
| ▼ Q2 FY2025 | May 7, 2025 | $0.11 | $0.10 | -9.1% | $0.02B | $0.02B | -5.0% |
| ▼ Q1 FY2025 | Mar 18, 2025 | $0.21 | $0.13 | -38.1% | $0.02B | $0.02B | -0.8% |
| ▼ Q4 FY2024 | Nov 7, 2024 | $0.14 | $0.01 | -92.9% | $0.01B | $0.01B | -0.9% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.29
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.33
EPS Est.
$0.19
EPS Surpr.
+77.7%
Revenue
$0.02B
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
$0.70
EPS Est.
$0.21
EPS Surpr.
+228.8%
Revenue
$0.02B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$0.30
EPS Est.
$0.21
EPS Surpr.
+43.8%
Revenue
$0.02B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$0.30
EPS Est.
$0.21
EPS Surpr.
+41.1%
Revenue
$0.02B
Q2 FY2025
May 7, 2025Miss
EPS Actual
$0.10
EPS Est.
$0.11
EPS Surpr.
-9.1%
Revenue
$0.02B
Q1 FY2025
Mar 18, 2025Miss
EPS Actual
$0.13
EPS Est.
$0.21
EPS Surpr.
-38.1%
Revenue
$0.02B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
$0.01
EPS Est.
$0.14
EPS Surpr.
-92.9%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.24 | $0.25 | $0.26 | 1 |
| Q3 FY2027 | $0.27 | $0.28 | $0.29 | 1 |
| Q2 FY2027 | $0.26 | $0.27 | $0.28 | 1 |
| Q1 FY2027 | $0.22 | $0.22 | $0.23 | 1 |
| Q4 FY2026 | $0.20 | $0.21 | $0.22 | 1 |
| Q3 FY2026 | $0.17 | $0.24 | $0.31 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +77.7% | $17.90 | $17.87 | -0.17% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +228.8% | $14.44 | $14.42 | -0.14% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +43.8% | $14.93 | $14.82 | -0.74% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +41.1% | $12.85 | $13.54 | +5.37% |
| ▼ Q2 FY2025 | May 7, 2025 | -9.1% | $14.40 | $14.34 | -0.42% |
| ▼ Q1 FY2025 | Mar 18, 2025 | -38.1% | $11.29 | $11.98 | +6.11% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -92.9% | $15.04 | $15.54 | +3.32% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +0.0% | $12.88 | $13.81 | +7.22% |
Q2 FY2026-0.17%
Report Date
May 7, 2026
EPS Beat/Miss
+77.7%
Price Before
$17.90
Price After
$17.87
Q1 FY2026-0.14%
Report Date
Mar 12, 2026
EPS Beat/Miss
+228.8%
Price Before
$14.44
Price After
$14.42
Q4 FY2025-0.74%
Report Date
Nov 6, 2025
EPS Beat/Miss
+43.8%
Price Before
$14.93
Price After
$14.82
Q3 FY2025+5.37%
Report Date
Aug 7, 2025
EPS Beat/Miss
+41.1%
Price Before
$12.85
Price After
$13.54
Q2 FY2025-0.42%
Report Date
May 7, 2025
EPS Beat/Miss
-9.1%
Price Before
$14.40
Price After
$14.34
Q1 FY2025+6.11%
Report Date
Mar 18, 2025
EPS Beat/Miss
-38.1%
Price Before
$11.29
Price After
$11.98
Q4 FY2024+3.32%
Report Date
Nov 7, 2024
EPS Beat/Miss
-92.9%
Price Before
$15.04
Price After
$15.54
Q3 FY2024+7.22%
Report Date
Aug 8, 2024
EPS Beat/Miss
+0.0%
Price Before
$12.88
Price After
$13.81
Avg Beat Reaction+2.31%
Avg Miss Reaction+3.00%
Beat Rate5 / 8 quarters
Largest Move+7.22% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CPH.TO ends December
Cipher Pharmaceuticals Inc. (CPH.TO) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.33 — beating the analyst consensus of $0.19 by +77.7%. CPH.TO has beaten EPS estimates for 4 consecutive quarters. The next CPH.TO earnings date is expected around September 1, 2026.
Each quarter, investors track CPH.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CPH.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CPH.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CPH.TO earnings · 5 questionsCipher Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. CPH.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CPH.TO historically reports after market close (AMC).
CPH.TO earnings datewhen is CPH.TO earningsCPH.TO next earnings datewhen does CPH.TO report earningsCPH.TO earnings calendar
▸ Source: FMP · Cipher Pharmaceuticals Inc. SEC filings · US GAAP · Cipher Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026